UNITEDHEALTH GROUP INCUNH
UNITEDHEALTH GROUP INC Financial Overview 2020–2024
Medical costs surged 21% year-over-year in Q3 2025, driving the Medical Care Ratio to a startling 89.9% and slicing operating earnings by 50%. This rapid margin deterioration signals a structural reset for the healthcare giant, driven by Medicare Advantage funding cuts and elevated patient utilization. While the top-line growth engine remains intact—total revenue expanded from $257.1 billion in FY2020 to $400.3 billion in FY2024—the company is struggling to convert that massive scale into immediate profit growth.
The operational headwinds are broad-based and severe. In Q3 2025, Optum Health saw operating earnings collapse by 88%, overshadowing a 12% increase in total quarterly revenue to $113.2 billion. This volatility follows a chaotic FY2024, which included a $7.1 billion loss on the sale of Brazil operations and over $2.2 billion in direct costs stemming from the Change Healthcare cyberattack. Despite these liquidity pressures, management has maintained aggressive capital returns, repurchasing $9 billion of stock in FY2024 and raising the annual dividend rate to $8.40 per share.
Recent Developments (Q2 and Q3 2025)
Margin pressures accelerated earlier in the year, with Q2 2025 operating earnings falling 35% to $5.2 billion despite a 13% revenue increase to $111.6 billion. This profitability compression worsened due to rising utilization, though the Optum Insight segment provided a rare counterbalance in Q3 2025, delivering a 46% spike in operating income even as care delivery margins collapsed. On the strategic front, the company finalized its acquisition of Amedisys in August 2025, a move expected to be modestly dilutive initially but critical for long-term home health capabilities. Additionally, former FDA Commissioner Scott Gottlieb joined the board in November 2025, signaling a renewed focus on navigating the complex regulatory environment.
Bulls point to the addition of over 1.03 million consumers in Q2 2025 as proof of enduring market share gains, while bears argue the valuation of 23.7x earnings as of October 2025 is difficult to justify amid contracting profits.
What to watch: Amedisys integration costs; impact of 2026 Star Ratings on reimbursement levels.
Rev
$400.28B
FY2024
NI
$14.40B
FY2024
EPS
$15.64
FY2024
OCF
$24.20B
FY2024
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
UNITEDHEALTH GROUP INC 8-K Report, Financial Results (Jan 27, 2026)
UnitedHealth Group Inc. (UNH) has filed an 8-K report on January 26, 2026, to announce its fourth quarter and full year 2025 financial results. While the 8-K itself does not contain the detailed financial figures, it directs investors to a press release (Exhibit 99.1) and a linked PDF document (Exhibit 99.2) furnished with the filing. These accompanying documents are the primary source for understanding UNH's operational performance and financial condition for the period ended December 31, 2025. Investors should refer to the press release and the linked PDF for specific details on revenue, earnings per share, medical cost ratios, growth within its UnitedHealthcare and Optum segments, and forward-looking guidance. The filing indicates that this information is incorporated by reference, making it crucial for a comprehensive understanding of the company's recent performance and future outlook. The inclusion of an Interactive Data File in Inline XBRL format further suggests a commitment to transparency and ease of data analysis.
UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Jan 12, 2026)
UnitedHealth Group Inc. (UNH) has filed a Current Report (8-K) on January 12, 2026, primarily to disclose information regarding upcoming investor meetings on January 12, 2026. During these meetings, the company's senior management intends to reaffirm previously issued guidance for adjusted 2025 earnings per share (EPS), which was originally provided on October 28, 2025. It is crucial for investors to note that the company's financial closing procedures for the full year 2025 are not yet finalized. Consequently, actual reported results could differ from the reaffirmed expectations. This potential variance is attributed to ongoing financial closing procedures, final adjustments, management review, and other developments that may occur before the official finalization of the 2025 financial results.
UNITEDHEALTH GROUP INC 8-K Report, Executive Changes (Nov 21, 2025)
UnitedHealth Group Inc. (UNH) has announced a significant addition to its Board of Directors with the appointment of Scott Gottlieb, M.D., as an independent director, effective immediately. Dr. Gottlieb brings a wealth of experience from his tenure as FDA Commissioner, where he focused on enhancing transparency, patient safety, and market competition, alongside initiatives in medical innovation and public health crises. His background also includes roles at CMS and a strong presence in health policy and investment. This appointment is noteworthy for investors given Dr. Gottlieb's recognized expertise in healthcare regulation, policy, and innovation. His insights are expected to be valuable as UNH navigates the complex and evolving healthcare landscape, potentially influencing strategic decisions related to regulatory affairs, market dynamics, and the adoption of new technologies. The company will compensate Dr. Gottlieb according to its standard director compensation program and has entered into an indemnification agreement.
UNITEDHEALTH GROUP INC 8-K Report, Bylaw Amendment (Nov 13, 2025)
UnitedHealth Group Inc. (UNH) filed an 8-K on November 12, 2025, to report a minor administrative change. The Company's Board of Directors approved an amendment to its Amended and Restated Bylaws, effective November 6, 2025. The sole purpose of this amendment was to update the registered office and registered agent of the Company in the State of Delaware. This filing does not contain any material financial updates or operational changes that would directly impact the company's performance or investor outlook.
UNITEDHEALTH GROUP INC 8-K Report, Regulation FD Disclosure (Nov 7, 2025)
UnitedHealth Group Inc. (UNH) has filed an 8-K report to disclose an upcoming investor event. Senior leadership will be participating in an interview at the UBS Global Healthcare Conference 2025 on November 10, 2025. This session is expected to cover the company's strategic initiatives, competitive positioning within its markets, recent financial performance, and outlook for its various business segments. Investors seeking forward-looking insights and a deeper understanding of UNH's operational strategy and market expectations should pay close attention to this conference. While this 8-K itself does not contain new financial data or material updates, it serves as a notification for a key opportunity to glean qualitative and potentially quantitative information directly from the company's leadership. The event will be accessible via a live audio webcast on the company's Investor Relations website, allowing for broad investor participation.
View all 8-K filings →